One delay column solution helps laboratories simplify workflows, reduce system interference and future-proof PFAS methods for emerging compounds TORRANCE, CA, - Phenomenex Inc., a Danaher Company and a global leader in the research and manufacture of advanced technologies for the separation sciences, today announced the launch of the PFAS Universal Delay Column, a new addition to its Designed [...]

Qmicro by Sensirion announces the launch of the DynamiQ-X universal, a new addition to the DynamiQ-X series and a breakthrough in globally deployable micro-gas chromatograph technology. Engineered for organizations operating in demanding industrial and hazardous environments, the DynamiQ-X universal delivers true international readiness without compromise. Certified to ATEX, IECEx and cQPSus, the DynamiQ-X universal meets [...]

Supporting ADLM's focus on collaborative, cross-disciplinary solutions that address laboratory workforce and operational challenges Highlighting innovations in mass spectrometry, next-generation sequencing, digital pathology and AI diagnostics Showcasing Roche's portfolio across core, molecular and pathology labs and point-of-care settings at booth no. 2901 INDIANAPOLIS -- (SIX: RO, ROP; OTCQX: RHHBY) As clinical laboratories face ongoing staffing [...]

immunoMUSE® enables flexible, high-sensitivity multiplex immunofluorescence with user-defined antibodies. Schlieren, Switzerland – arcoris bio, a Swiss life science research tools and in vitro diagnostics company, today announced a distribution partnership with Europa Biosite, a leading distributor of life science research products and services. Through this partnership, Europa Biosite will distribute arcoris bio’s newly launched immunoMUSE® kits in [...]

Technology License Partnership provides Genentech access to MaxCyte’s portfolio of platform technologies across research, development, and manufacturing workflows ROCKVILLE, Md. -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell-based therapeutics, today announced that it has entered into a technology license partnership [...]

Backed by KKR’s £4.7 billion acquisition of Malvern Panalytical parent company Spectris, the materials characterization leader enters a new era of innovation, customer focus, and long-term ambition. Malvern, UK, Sciad Communications -- Malvern Panalytical is setting an ambitious new course for growth, with Christian Sauber, Ph.D., as President and following the acquisition of its parent company Spectris [...]

Partnership combines Sirona Dx‘s technology-agnostic spatial biology expertise with Parhelia‘s Spatial Station platform to improve reproducibility, increase throughput, and reduce costs across spatial biology workflows. ASHLAND, Ore. and PORTLAND, Ore. — Parhelia Biosciences and Sirona Dx today announced a strategic partnership aimed at advancing the adoption of spatial biology in translational research, clinical trials, and precision health [...]

TUCSON, Ariz. -- Clinisys, a global leader in laboratory informatics, today announced the general availability of Clinisys™ Laboratory Solution (CLS) v2025.3, continuing the evolution of its unified platform for scientific and healthcare laboratories. The release extends CLS with enhanced configuration, expanded interoperability, integrated analytics, and governed AI capabilities—helping laboratories simplify operations, improve visibility, and scale [...]

Milestone Reflects Deepening Customer Centricity as DNAnexus Continues to Scale its Platform for the World's Leading Life Sciences Organizations, Accelerating Growth By Global Expansion MOUNTAIN VIEW, Calif. -- Today, DNAnexus, the world's most trusted platform for omics data enablement, announced it has achieved a 90% customer satisfaction score (CSAT) — a milestone underscoring the trust [...]

Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expected new program clinical starts Includes headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas with overall response rate of 84%, complete response rate of 32% and no [...]